389 related articles for article (PubMed ID: 28000527)
21. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy.
Sigalotti L; Coral S; Fratta E; Lamaj E; Danielli R; Di Giacomo AM; Altomonte M; Maio M
Semin Oncol; 2005 Oct; 32(5):473-8. PubMed ID: 16210088
[TBL] [Abstract][Full Text] [Related]
22. Molecular and Cellular Changes During Cancer Progression Resulting From Genetic and Epigenetic Alterations.
Pruitt K
Prog Mol Biol Transl Sci; 2016; 144():3-47. PubMed ID: 27865461
[TBL] [Abstract][Full Text] [Related]
23. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
Manieri NA; Chiang EY; Grogan JL
Trends Immunol; 2017 Jan; 38(1):20-28. PubMed ID: 27793572
[TBL] [Abstract][Full Text] [Related]
24. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
26. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; CalabrĂ² L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
Yin J; Gu T; Chaudhry N; Davidson NE; Huang Y
Front Immunol; 2023; 14():1325615. PubMed ID: 38268926
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
30. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.
McLane LM; Abdel-Hakeem MS; Wherry EJ
Annu Rev Immunol; 2019 Apr; 37():457-495. PubMed ID: 30676822
[TBL] [Abstract][Full Text] [Related]
31. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges.
Gerhauser C
Top Curr Chem; 2013; 329():73-132. PubMed ID: 22955508
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation of immune escape genes in cancer.
Tomasi TB; Magner WJ; Khan AN
Cancer Immunol Immunother; 2006 Oct; 55(10):1159-84. PubMed ID: 16680460
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of cancers comes of age.
Yousefi H; Yuan J; Keshavarz-Fathi M; Murphy JF; Rezaei N
Expert Rev Clin Immunol; 2017 Oct; 13(10):1001-1015. PubMed ID: 28795649
[TBL] [Abstract][Full Text] [Related]
34. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.
Sanchez-Correa B; Lopez-Sejas N; Duran E; Labella F; Alonso C; Solana R; Tarazona R
Cancer Immunol Immunother; 2019 May; 68(5):861-870. PubMed ID: 30953117
[TBL] [Abstract][Full Text] [Related]
35. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Torphy RJ; Schulick RD; Zhu Y
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211042
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
Ahuja N; Sharma AR; Baylin SB
Annu Rev Med; 2016; 67():73-89. PubMed ID: 26768237
[TBL] [Abstract][Full Text] [Related]
37. Epigenetics in cancer: Fundamentals and Beyond.
Biswas S; Rao CM
Pharmacol Ther; 2017 May; 173():118-134. PubMed ID: 28188812
[TBL] [Abstract][Full Text] [Related]
38. A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.
Liu Z; Ren Y; Weng S; Xu H; Li L; Han X
Front Immunol; 2022; 13():809761. PubMed ID: 35140720
[TBL] [Abstract][Full Text] [Related]
39. [Immune-checkpoints: the new anti-cancer immunotherapies].
Ileana E; Champiat S; Soria JC
Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]